The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.

Détails

ID Serval
serval:BIB_510E90C30673
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.
Périodique
Radiation Oncology
Auteur(s)
Zimmermann M., Zouhair A., Azria D., Ozsahin M.
ISSN
1748-717X[electronic]
Statut éditorial
Publié
Date de publication
2006
Volume
1
Pages
11
Langue
anglais
Notes
Publication types: Journal Article
Résumé
Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-alpha) results in activation of intracellular tyrosine kinase, therefore, cell cycle progression. High levels of EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN). Blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the receptor, therefore, in inhibition of cell proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and metastases. The EGFR is a prime target for new anticancer therapy in SCCHN, and other agents in development include small molecular tyrosine kinase inhibitors and antisense therapies.
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/01/2008 18:20
Dernière modification de la notice
08/05/2019 18:33
Données d'usage